D'Angelo Daniela, Mussnich Paula, Arra Claudio, Battista Sabrina, Fusco Alfredo
Istituto di Endocrinologia ed Oncologia Sperimentale del CNR, Via Pansini 5, 80131, Naples, Italy.
Istituto Nazionale per lo Studio e la Cura dei Tumori "Fondazione Giovanni Pascale", IRCCS, Naples, Italy.
J Mol Med (Berl). 2017 Apr;95(4):353-360. doi: 10.1007/s00109-017-1520-x. Epub 2017 Mar 14.
The high-mobility group A (HMGA) proteins are frequently overexpressed in human malignancies and correlate with the presence of metastases and reduced patient survival. Here, we highlight the main studies evidencing a critical role of HMGA in chemoresistance, mainly by activating Akt signaling, impairing p53 activity, and regulating the expression of microRNAs that target genes involved in the susceptibility of cancer cells to antineoplastic agents. Therefore, these studies account for the association of HMGA overexpression with patient poor outcome, indicating the impairment of HMGA as a fascinating perspective for effectively improving cancer therapy.
高迁移率族蛋白A（HMGA）在人类恶性肿瘤中经常过度表达，与转移的存在及患者生存率降低相关。在此，我们重点介绍主要研究，这些研究证明HMGA在化疗耐药中起关键作用，主要是通过激活Akt信号传导、损害p53活性以及调节靶向参与癌细胞对抗肿瘤药物敏感性相关基因的微小RNA的表达。因此，这些研究解释了HMGA过表达与患者不良预后的关联，表明抑制HMGA是有效改善癌症治疗的一个引人关注的方向。
